

cyclosporin complexed to the FAB fragment of an antibody.

The results lead to following conclusion: Cyclosporin has in solid state 4 different stable conformations, the first one occurs in cyclosporin A monohydrate, cyclosporin A dihydrate, and cyclosporin H, the second is common for thio-cyclosporin and cyclosporin A arilsolv solvate, the third is typical for all complexes of cyclosporin with cyclophilin and the fourth one was found for the cyclosporin complex with the FAB fragment of an antibody.

PS05.02.07 CENTROSYMMETRIC CRYSTALS OF A DESIGNED, ALPHA-HELICAL PEPTIDE. William R. Patterson and David Eisenberg, UCLA-DOE Laboratory of Structural Biology and Molecular Medicine and Department of Chemistry and Biochemistry, University of California, Los Angeles, California.

We are exploring the packing interactions of *de novo* designed, alpha-helical peptides in racemic mixtures for use as novel biomaterials. Crystals of the 12-residue peptide, α -1 (1) were produced by vapor diffusion methods in the presence of both peptide enantiomers. X-ray diffraction data were collected at 92 K and were 87% complete to 2.1 Å with a scaling R-factor of 13.7%. The crystals indexed initially in space group P1 with $a=20.79$ Å, $b=20.35$ Å, $c=27.95$ Å, $\alpha=101.48^\circ$, $\beta=97.77^\circ$, and $\gamma=120.88^\circ$. These unit cell parameters are nearly identical to the P1 unit cell of the L- α -1 enantiomer of known structure (2). To test for the presence of inversion symmetry, a cumulative intensity distribution was calculated for the D,L- α -1 and L- α -1 intensity data. The intensity distributions show that the putative, racemic data follow the theoretical centric distribution while the L- α -1 data follow the theoretical acentric distribution. We conclude that the crystals are centrosymmetric and belong to space group P1bar, with 2 peptides in the asymmetric unit. Currently, we are optimizing the racemic crystallization condition to produce larger crystals in an effort to obtain higher resolution data for use with direct methods techniques.

References:

- 1) Eisenberg, D. et al (1986) The Design, Synthesis, and Crystallization of an Alpha-Helical Peptide. *Proteins* 1, 16-22.
- 2) Prive, G. et al. (1996) Packed Protein Bilayers in the 0.92 Å-Resolution Structure of a Designed Alpha-Helical Bundle. Manuscript in preparation.

PS05.02.08 THE 1.2 Å STRUCTURE OF G1, AN α -CONOTOXIN PEPTIDE. L. W. Guddat*, L. Shan#, J. L. Martin*, A. B. Edmundson#, W. R. Gray§* Centre for Drug Design & Development, U. Queensland, Brisbane 4072, QLD, Australia. #Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, USA. §201 So. Biology, University of Utah, Salt Lake City, UT 84112,

The crystal structure of a synthetic thirteen residue peptide that represents α -conotoxin G1 from marine snail *Conus Geographus* has been determined to 1.2 Å resolution. Structural studies of G1 are of particular interest because it is known to block synaptic transmission by binding to the acetylcholine receptor. This structure, which contains 117 atoms, was solved by direct methods implementing the program SHAKE-AND-BAKE[1]. The framework of the toxin includes two disulphide bonds that link residues 2-7 and 3-13. The side chain of the amino terminal residue and the amide from the carboxy terminus form a hydrogen bond, making the peptide in the shape of a closed loop. The two termini are further drawn together by additional main chain hydrogen bonds. The two positively charged regions, the amino terminus and the guanidinium group of arg-9 are separated by 15 Å, a value consistent with other acetylcholine agonists such as curare[2,3]. The X-ray structure of G1 will be compared with structures derived by NMR and a predictive model based on a CD spectrum[4-6].

1. Miller, R., Gallo, S. M., Khalak, H. G. & Weeks C. M. (1994) *J. Appl. Cryst.*, 27, 613-621.
2. Pauling, P. & Petcher, T. J. (1973) *Chem. Biol. Interact.*, 6, 351-365.
3. Hider, R. C. & Dufton, M. J. (1979) in *Natural Toxins* (Eakere, D. & Wadstrom, T., Eds.) pp 515-522, Pergamon, London
4. Pardi, A., Galdes, A., Florance, J. & Maniconte, D. (1989) *Biochemistry*, 28, 5494-5501
5. Kobayashi, Y., et al., & Go, N. (1989) *Biochemistry*, 28, 4853-4860.
6. Hider, R. C. (1985) *FEBS*, 184, 181-184.

PS05.02.09 FOLDING AND AGGREGATION OF HETERODIMERS OF GRAMICIDIN. W. L. Duax, B. Burkhart, D. Langs and W. Pangborn, Hauptman-Woodward Medical Research Inst., 73 High St., Buffalo, NY 14203-1196 USA

Full-matrix refinement of the three-dimensional structures of two crystal forms of wild type gramicidin, a D,L-pentadecapeptide, reveal the presence of heterodimers. Partially occupied tyrosine residues are found at position eleven on only one strand of the antiparallel double helix. The approximate ratio of 11-tyrosine to 11-tryptophan in the heterodimer agrees with typical estimates for the ratio of gramicidin C to gramicidin A in wild type gramicidin. The environments of the 11-substituent in the two crystal forms are distinctly different and include specific interactions with solvent. In the orthorhombic form, which crystallized from ethanol, a network of hydrogen bonds link the tyrosine in one double helix with the backbone of an adjacent helix through an ethanol molecule and a water molecule. In the monoclinic form there is no comparable system linking helices.

The presence of a heterodimer in crystal forms having significantly different crystal packing suggests that heterodimer formation is a property of the gramicidin and not induced by crystal formation. In our hands, efforts to crystallize pure gramicidin A have invariably failed to produce sizable crystals and crystals prepared from wild type gramicidin do not readily redissolve upon addition of more solvent. The heterodimer appears to be the most stable form of gramicidin and is critical to crystal nucleation. Dimers of gramicidin observed in the solid state are composed of two antiparallel β -strands wrapped into a cylindrical tube. Although